Bayer boosts cell therapy pipeline with BlueRock acquisition

Bayer has announced it is fully acquiring US cell therapy biotech BlueRock Therapeutics, whose cell therapy pipeline includes a treatment for Parkinson’s disease.

Finding the right reimbursement model for gene therapies

With cell and gene therapies growing more and more important to healthcare, we sat down with Debbie Warner, vice president of Kantar’s Health division, to learn how the industry can overcome fu

Catalyst’s rival to NovoSeven hits the mark in phase 2 haemo...

Oxford Biomedica signs ophthalmology R&D deal with Santen

UK biotech Oxford Biomedica and Japan’s Santen have begun an option and licence agreement to research and develop gene therapy products for an inherited retinal disease.

Continuous bioprocessing – the key to industrialising gene t...

A new partnership, with funding from Innovate UK, aims to investigate the possibility of using continuous manufacturing processes in gene therapy.